title: Weight, lipids, glucose, and behavioral measures with ziprasidone treatment in a population with mental retardation.
abstract: BACKGROUND
  Atypical antipsychotics effectively reduce maladaptive behavior in individuals with mental retardation, yet bring significant weight gain and metabolic anomalies. Ziprasidone, a weight-neutral antipsychotic in patients with schizophrenia or schizoaffective disorder, has not been studied in a population with mental retardation and maladaptive behaviors.
  
  
  METHODS
  Forty patients with mental retardation and maladaptive behaviors who had gained excessive weight or were inadequately responsive to other agents were switched to ziprasidone. Weight, total cholesterol, HDL, LDL, triglycerides, and frequency of maladaptive behavior were recorded at baseline and after 6 months of ziprasidone treatment.
  
  
  RESULTS
  Ziprasidone treatment was associated with a significant weight loss of 8.1 lb (3.6 kg) as well as a significant reduction in total cholesterol and triglycerides (p < or =.05). The monthly frequency of the maladaptive behavior remained unchanged or improved in 72% (18/25) of the patients in whom maladaptive behavior was assessed.
  
  
  CONCLUSIONS
  Ziprasidone effectively reduces the frequency of maladaptive behavior in a patient group with mental retardation without causing weight gain or metabolic disturbances.
authors.affiliation: sacohenmd@msn.com
authors.forename: Seth
authors.initials: S
authors.lastname: Cohen
authors.forename: Brian
authors.initials: B
authors.lastname: Fitzgerald
authors.forename: Anthony
authors.initials: A
authors.lastname: Okos
authors.forename: Shirin
authors.initials: S
authors.lastname: Khan
authors.forename: Arif
authors.initials: A
authors.lastname: Khan
mesh_terms: D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001786:Blood Glucose / Q000187:drug effects*; D001835:Body Weight / Q000187:drug effects*; D002784:Cholesterol / Q000097:blood; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008607:Intellectual Disability / Q000097:blood / Q000523:psychology / Q000534:rehabilitation*; D008055:Lipids / Q000097:blood*; D008297:Male; D001523:Mental Disorders / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D008875:Middle Aged; D010879:Piperazines / Q000008:administration & dosage / Q000627:therapeutic use*; D011569:Psychiatric Status Rating Scales; D013844:Thiazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood
chemical_list: D014150:Antipsychotic Agents; D001786:Blood Glucose; D008055:Lipids; D010879:Piperazines; D013844:Thiazoles; D014280:Triglycerides; C092292:ziprasidone; D002784:Cholesterol